No Data
No Data
Zhejiang Jianfeng Group (600668.SH) subsidiary Jianfeng Pharmaceuticals passed the on-site inspection by the USA FDA.
Zhejiang Jianfeng Group (600668.SH) announced that its wholly-owned subsidiary, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (abbreviated as "..."
Zhejiang Jianfeng Group (600668.SH) subsidiary Er Ying Company has obtained the pharmaceutical registration certificate.
The zhejiang jianfeng group (600668.SH) announced that recently, the company's wholly-owned subsidiary zhejiang jianfeng pharmaceutical co., ltd. (abbreviated as...
Zhejiang Jianfeng's Pharmaceutical Arm Gets Nod to Market Diquafosol Sodium Eye Drops
Zhejiang Jianfeng Group (600668.SH): Dioketol sodium eye drops obtained the pharmaceutical registration certificate.
On December 4th, Gelonghui reported that zhejiang jianfeng group (600668.SH) announced that its wholly-owned subsidiary, zhejiang jianfeng pharmaceutical co., ltd., received the Drug Registration Certificate for Diquafosol Sodium Eye Drops issued by the National Medical Products Administration. Diquafosol Sodium Eye Drops are jointly developed by Santen Pharmaceutical Co., Ltd. from japan and Inspire Pharmaceuticals from the usa, used for the treatment of dry eye syndrome, with a specification of 3% (5ml:150mg), since 2010.
zhejiang jianfeng group (600668.SH): Subsidiary passes pharmaceutical GMP compliance inspection.
On November 13, Gelonhui announced that its wholly-owned subsidiary, Zhejiang Jianfeng Pharmaceutical Co., Ltd., obtained the announcement of the results of pharmaceutical GMP compliance inspection from the Zhejiang Provincial Food and Drug Administration website. This pharmaceutical GMP compliance inspection result obtained by Jianfeng Pharmaceutical indicates that the production lines of the subsidiary comply with GMP requirements, which is beneficial to ensuring product quality and production capacity, establishing a stable production capacity, and further enriching the company's product line.
Zhejiang Jianfeng Group's (SHSE:600668) Anemic Earnings Might Be Worse Than You Think
No Data